Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 9/20 | 0.43 |
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | ACE | P12821 | 4/20 | 0.43 |
| ▸ | CPA1 | P15085 | 4/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20816679 | 1.00 | CTSL (0.45) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816897 | 0.96 | MME (0.45) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816895 | 0.96 | MME (0.45) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816712 | 0.96 | MME (0.45) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816756 | 0.96 | MME (0.45) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816930 | 0.95 | PTPN1 (0.43) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816907 | 0.95 | CTSL (0.41) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816582 | 0.95 | CTSL (0.41) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20816688 | 0.95 | CTSS (0.41) | CTSLCTSBCTSSCTSDMME | |
| SCHEMBL20827936 | 0.95 | PTPN1 (0.43) | CTSLCTSBCTSSCTSDMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | Phelix Therapeutics (US) | 2019-03-21 | — | — | US | claimed |
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | Phelix Therapeutics (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | Phelix Therapeutics (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | CTSS, CTSB, CTSL | CTSL 3/4885CTSB 2/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.